

Memorandum

PREPARED FOR: Senate Committee on Rules
DATE: January 30, 2024
BY: Leslie Porter, Analyst
RE: Legislative Review of Executive Appointments



LPRO
LEGISLATIVE POLICY
AND RESEARCH OFFICE

PRESCRIPTION DRUG AFFORDABILITY BOARD

The Governor has appointed the following individual to the Prescription Drug Affordability Board, subject to Senate confirmation:¹

New Appointment

Christopher Laman of Astoria

Term

February 16, 2024 – December 31, 2025

Statutory Authority

[ORS 646A.693 \(2023\)](#).

Statement of Economic Interest²

Not required.

Composition³

The board consists of eight Oregon residents with expertise in health care economics and clinical medicine, serving staggered terms:⁴

- two members shall serve for a term ending December 31, 2024 (BURNS, MURRY);
- three members shall serve for a term ending December 31, 2025 (BRUNO, HARTUNG, **LAMAN**); and
- three members, including the chair, shall serve for a term ending December 31, 2026 (BAILEY, PATTERSON, JUDGE).

Subsequent members serve four-year terms and are eligible for reappointment. Individuals employed by drug manufacturers or their trade associations are prohibited. The board selects its chair and vice chair. The board is required to meet once every six weeks at, so long as there are prescription drugs under review.

¹ [Or. Const. art. III, sect. 4](#); [ORS 171.562 and 171.565 \(2023\)](#).

² [ORS 244.050 \(2023\)](#).

³ [ORS 182.100 \(2023\)](#) for affirmative action policy; [ORS 236.115 \(2023\)](#) for diversity criteria.

⁴ [ORS 646A.693 \(2023\)](#)

Duties⁵

The board is established in the Department of Consumer Affairs and Business Services (DCBS) to protect residents, state and local governments, commercial health plans, health care providers, pharmacies, and other stakeholders from the high costs of prescription drugs. The board must also:

- identify at least nine drugs and one insulin product annually as specified that it determines will pose cost challenges for patients or health care systems;
- report to the legislature and the Health Care Cost Growth Target program annually as specified, on price trends and drugs that were reviewed; and,
- study the national market for generic drugs as specified and report to the legislature annually.

⁵ [ORS 646A.693 to 616A.697 \(2023\)](#)



Prescription Drug Affordability Board

Agency: **Consumer & Business Services, Department of**

Policy Area: **Health**

Authorization: **646A.693; SB 844 (2021)**

Board Admin: **Ralph Magrish**

Min Members: **5** Max Members: **8**

Address:

Term Length: **4** Term Limit: **None**

,

Senate Confirmation Required?: **Yes**

Ralph.M.MAGRISH@dcbs.oregon.gov

Current Appointments

Patterson, Akil

Term(s): **6/10/2022 - 12/31/2026**

Primary Member

Position Number: **1**

Bailey, Shelley

Term(s): **6/10/2022 - 12/31/2026**

Primary Member

Position Number: **2**

Bruno, Richard

Term(s): **6/10/2022 - 12/31/2025**

Primary Member

Position Number: **3**

Hartung, Daniel

Term(s): **6/10/2022 - 12/31/2025**

Primary Member

Position Number: **4**

Dr Burns, Amy M

Term(s): **9/28/2022 - 12/31/2024**

Primary Member

Position Number: **5**

Mr Judge, Robert M

Term(s): **6/10/2022 - 12/31/2026**

Primary Member

Position Number: **6**

Laman, Christopher

Term(s): **2/16/2024 - 12/31/2025**

Primary Member

Position Number: **7**

Murray, John

Term(s): **9/28/2022 - 12/31/2024**

Primary Member

Position Number: **8**

Vacant Positions